Key Takeaways
- •Participants in the OASIS 4 trial who qualified as early responders to oral semaglutide 25 mg experienced 21.6% weight loss.
- •Nearly three-quarters of patients on oral semaglutide 25 mg failed to achieve the 10% weight loss threshold by week 16.
- •Physicians gain data-backed reasons to encourage patients with slower initial progress to continue treatment.
Weight Loss Outcomes in OASIS 4 Trial
Participants in the OASIS 4 trial who qualified as early responders to oral semaglutide 25 mg experienced 21.6% weight loss. Early responders represented 28.8% of the study group, defined by reaching at least 10% weight loss by week 16. This figure highlights the proportion who met that specific early benchmark.
Nearly three-quarters of patients on oral semaglutide 25 mg failed to achieve the 10% weight loss threshold by week 16. However, these individuals still recorded 11.5% body weight reduction by week 64. Such results provide a clinically significant outcome that shifts focus on early response toward tools for dose adjustment and patient guidance.
Physicians gain data-backed reasons to encourage patients with slower initial progress to continue treatment. This approach treats early response less as a selection criterion and more as a means to manage expectations. The findings support ongoing therapy despite modest early results.
Physical Function Improvements
The trial revealed notable gains in physical function among those with poor baseline performance. These participants faced challenges in bending, standing, or maintaining activity. In this group, 77.3% attained clinically meaningful improvements in function scores, compared to 42.9% receiving placebo.
This roughly doubled improvement rate persisted even after accounting for similar weight loss in the subgroup versus the full cohort. The data indicate that benefits to function extend beyond weight reduction alone. Separating direct effects of GLP-1 agonism on muscles and mobility from those driven by weight loss remains a challenge for trial designs.
Future studies in this drug class must address this separation through targeted endpoints. Such clarity would better define the contributions to musculoskeletal and mobility results. The physical function findings warrant greater focus than currently received.
Indirect Comparison with Orforglipron
Novo Nordisk shared results from the ORION indirect treatment comparison versus orforglipron. The analysis showed about 14 times greater odds of gastrointestinal-related discontinuation for the Eli Lilly drug. Indirect comparisons involve limitations like varying trial populations, titration plans, and endpoints.
Presenting these at a congress without direct head-to-head trials serves both competitive and scientific aims. The OPTIC survey reported an 84% patient preference figure, yet such studies reflect one compound's characteristics and lack neutrality. Regulators disregard this type of evidence.
Payers may consider it differently. These elements add to the competitive context around oral options. The comparisons underscore tolerability differences claimed by Novo Nordisk.
Path to EMA Approval and Reimbursement
As oral semaglutide advances toward EMA approval, one key metric stands out: the 77.3% physical function responder rate. This applies particularly to populations facing obesity-related mobility impairment. Health technology assessment bodies will evaluate how they value this rate.
Should this endpoint support a claim for a specific patient subgroup, it alters reimbursement discussions. The argument strengthens not only against the injectable form but also versus other oral competitors. Such a positioning could reshape access for the pill formulation.
The data from OASIS 4 provide empirical support for broader counseling on persistence. Physical function gains offer a distinct angle amid weight loss results. Overall, the trial outcomes inform clinical and regulatory considerations.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg | >99% | 10mg | $49.00 |